PLX Protalix BioTherapeutics Inc

Price (delayed)

$2.325

Market cap

$187.33M

P/E Ratio

12.24

Dividend/share

N/A

EPS

$0.19

Enterprise value

$154.1M

?
Relative Growth: Rel. Growth: 88
Relative Strength: Rel. Strength: 65
Relative Valuation: Rel. Valuation: 93
Relative Profitability: Rel. Profitability: 98

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix was the first company to ...

Highlights
The gross profit has surged by 108% since the previous quarter and by 79% year-on-year
Protalix BioTherapeutics's equity has increased by 49% YoY and by 39% QoQ
PLX's debt has soared by 62% YoY

Key stats

What are the main financial stats of PLX

PLX stock price

How has the Protalix BioTherapeutics stock price performed over time
Intraday
-1.06%
1 week
7.14%
1 month
10.19%
1 year
57.09%
YTD
29.17%
QTD
7.14%

Financial performance

How have Protalix BioTherapeutics's revenue and profit performed over time
Revenue
$76.38M
Gross profit
$53.44M
Operating income
$19.79M
Net income
$15.33M
Gross margin
70%
Net margin
20.1%
The gross profit has surged by 108% since the previous quarter and by 79% year-on-year
Protalix BioTherapeutics's revenue has increased by 45% from the previous quarter and by 28% YoY
Protalix BioTherapeutics's gross margin has increased by 43% QoQ and by 40% YoY

Price vs fundamentals

How does PLX's price correlate with its fundamentals

Growth

What is Protalix BioTherapeutics's growth rate over time

Valuation

What is Protalix BioTherapeutics stock price valuation
P/E
12.24
P/B
2.79
P/S
2.43
EV/EBIT
7.41
EV/EBITDA
6.9
EV/Sales
2.02
Protalix BioTherapeutics's equity has increased by 49% YoY and by 39% QoQ
Protalix BioTherapeutics's revenue has increased by 45% from the previous quarter and by 28% YoY
PLX's price to sales (P/S) is 29% higher than its 5-year quarterly average of 1.9 and 2.5% higher than its last 4 quarters average of 2.4

Efficiency

How efficient is Protalix BioTherapeutics business performance
PLX's return on sales has surged by 178% year-on-year
Protalix BioTherapeutics's return on equity has surged by 168% YoY
The return on invested capital has surged by 131% year-on-year

Dividends

What is PLX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PLX.

Financial health

How did Protalix BioTherapeutics financials performed over time
PLX's total assets is 191% greater than its total liabilities
PLX's total assets is up by 38% year-on-year and by 24% since the previous quarter
Protalix BioTherapeutics's quick ratio has increased by 33% QoQ and by 23% YoY
PLX's debt is 87% less than its equity
PLX's debt has soared by 62% YoY
Protalix BioTherapeutics's equity has increased by 49% YoY and by 39% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.